- What is the ADPD conference?
- Why attend an Alzheimer’s or Parkinson’s conference in 2026?
- Top Alzheimer’s and Parkinson’s conferences in 2026
- How to choose the right conference for your research
- If your research spans both Alzheimer’s and Parkinson’s
- If your research is specifically in Alzheimer’s disease
- If your research is specifically in Parkinson’s disease
- If you want to present and get published in 2026
- If you are a basic neuroscientist working on disease mechanisms
- Useful guides for researchers and conference attendees
- Frequently asked questions — Alzheimer’s and Parkinson’s conferences 2026
- What is the ADPD conference?
- When and where was ADPD 2026?
- What is the next ADPD conference after 2026?
- Is there an Alzheimer’s and Parkinson’s conference in the USA in 2026?
- What is the difference between ADPD and AAIC?
- Where can I present Parkinson’s or Alzheimer’s research in 2026 with abstract submission still open?
- Plan your neurodegenerative disease conference calendar
Alzheimer’s and Parkinson’s diseases together affect over 60 million people worldwide. The research community working on these conditions is global, fast-moving, and dependent on a strong conference calendar to share findings, challenge therapies, and form the collaborations that lead to the next generation of treatments.
2026 has been one of the most significant years in neurodegenerative disease research in recent memory — with breakthroughs in biomarkers, gene therapy, and disease-modifying treatments presented at events across Copenhagen, London, Phoenix, and Seoul. This guide covers the most important Alzheimer’s and Parkinson’s conferences of 2026 and the key upcoming events already confirmed for 2027.
For researchers in neurology and neuroscience more broadly, see our full list of top neuroscience conferences in 2026.
What is the ADPD conference?
Before covering the full list, it is worth explaining what the ADPD conference is — because it is the central annual event in this field and the benchmark against which all other Alzheimer’s and Parkinson’s conferences are measured.
The AD/PD™ Conference — short for Alzheimer’s Disease and Parkinson’s Disease — is the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. It is widely considered the main annual meeting in the field of neurodegenerative diseases.
What makes it distinctive is its integrative approach. Most neurology conferences cover either Alzheimer’s or Parkinson’s separately. ADPD brings them together in a single scientific programme — examining their shared mechanisms, their differences, and the overlapping biology that makes understanding one condition directly relevant to understanding the other.
The conference covers disease mechanisms and protein aggregation, early diagnosis and biomarkers, drug development and clinical trials, translational research from laboratory to clinic, genomics and genetic risk factors, and prevention strategies. It attracts a multidisciplinary mix of basic scientists, clinical researchers, industry professionals, and early-career researchers — making it one of the most diverse neuroscience gatherings on the calendar.
ADPD 2026 took place March 17–21 at the Bella Center in Copenhagen, Denmark. The next edition — AD/PD™ 2027 — is confirmed for March 16–20, 2027 in Barcelona, Spain. The official site is adpd.kenes.com.
Why attend an Alzheimer’s or Parkinson’s conference in 2026?
For researchers and clinicians working in neurodegenerative diseases, conferences are not optional professional development — they are where the field moves. Clinical trial results, biomarker breakthroughs, and new therapeutic targets are presented at conferences months or years before they reach journal publication or clinical guidelines.
Here is what you gain by attending the right event:
- Hear the most significant clinical trial results before they are published — directly from the research teams.
- Present your own research to an international specialist audience and receive methodologically informed peer feedback.
- CME and CPD credits for licence renewal — most major events offer 15–26+ accredited hours.
- Build research collaborations with labs and clinical teams from 60+ countries working on shared problems.
- Track the shift toward biomarker-driven, genetically targeted, and AI-assisted approaches to diagnosis and treatment.
Top Alzheimer’s and Parkinson’s conferences in 2026
1. ★ International Neurology Conference 2026 — PubScholars (Boston, USA)
Date: November 20–21, 2026
Location: Aloft Boston Seaport District, 401–403 D St, Boston, MA 02210, USA (Hybrid — in-person and virtual)
Theme: “Next-Generation Neurology: Integrating AI, Genomics & Clinical Excellence”
The International Neurology Conference 2026 is the most accessible event on this list for researchers working on Alzheimer’s, Parkinson’s, and related neurodegenerative conditions who want to present their work internationally and get it published. The conference covers Alzheimer’s disease and dementia research, Parkinson’s disease and movement disorders, neurodegeneration and protein aggregation, AI in neurological diagnosis, neuroimaging innovations, genomics in neurology, and clinical trial updates.
Both in-person and virtual attendance are fully supported. Submitted abstracts are reviewed by an international scientific committee with members from the USA, Portugal, China, and beyond. Accepted papers are published in official conference proceedings. Virtual attendees receive full session access and a digital certificate.
Who should attend: Neurologists, neuroscience researchers working on Alzheimer’s and Parkinson’s, neurodegenerative disease clinicians, pharmaceutical researchers in CNS, and postgraduate students presenting original research in neurodegeneration
CME / CPD Credits: CPD-accredited credits available for in-person and virtual attendees. Contact info@pubscholars.org
Abstract submission: https://pubscholars.org/submit-abstract/
Website: https://pubscholars.org/
Early Bird Registration closes June 30, 2026. Abstract submission is open.
2. AD/PD™ 2026 — International Conference on Alzheimer’s and Parkinson’s Diseases (Copenhagen)
Date: March 17–21, 2026 (already held)
Location: Bella Center, Copenhagen, Denmark (Hybrid — in-person and online)
Edition: 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
The 20th ADPD conference — held in March 2026 in Copenhagen — was the main neurodegenerative disease event of the year. ADPD brings together thousands of scientists, clinicians, and industry experts from over 60 countries to present the latest advances in research, clinical practice, and therapeutic innovation across Alzheimer’s, Parkinson’s, and related disorders including Huntington’s disease, ALS, frontotemporal dementia, and dementia with Lewy bodies.
The 2026 Copenhagen meeting featured major advances in APOE4 as a therapeutic target in Alzheimer’s, biomarker-driven approaches to early diagnosis, and the emerging biological era of Parkinson’s research. Abstract submission for 2026 closed September 17, 2025.
Planning ahead: AD/PD™ 2027 takes place March 16–20, 2027 in Barcelona, Spain. Abstract submission for 2027 opens in late 2026. Visit adpd.kenes.com for current details.
Who should attend: Neuroscientists, Alzheimer’s and Parkinson’s researchers, clinical neurologists, pharmaceutical industry researchers, biomarker specialists, and translational scientists working in neurodegeneration
CME / CPD Credits: CME/CPD accreditation available — verify on adpd.kenes.com
Website: https://adpd.kenes.com/
3. AAIC 2026 — Alzheimer’s Association International Conference (London)
Date: July 12–15, 2026
Location: ExCeL London, Royal Victoria Dock, London, UK (Hybrid — in-person and online)
The Alzheimer’s Association International Conference 2026 is the world’s largest gathering dedicated exclusively to Alzheimer’s disease and dementia research. AAIC is where the most significant dementia research announcements of the year are made — major clinical trial results, new disease-modifying therapy findings, and landmark biomarker discoveries are consistently unveiled here first.
The 2026 London meeting covers disease-modifying therapies, biomarkers for early detection, neuroinflammation, precision medicine approaches to Alzheimer’s, care and dementia services research, and the role of lifestyle factors in risk reduction. It is the top event specifically for Alzheimer’s researchers and clinicians.
Who should attend: Alzheimer’s disease researchers, dementia clinicians, clinical trialists, neuroscientists, pharmacologists in neurodegeneration, geriatric medicine specialists, and dementia care professionals
CME / CPD Credits: CME and CE credits available — verify on aaic.alz.org
Website: https://aaic.alz.org/
4. 7th World Parkinson Congress (WPC 2026) — Phoenix, Arizona, USA
Date: May 24–27, 2026
Location: Phoenix Convention Center, Phoenix, Arizona, USA
The 7th World Parkinson Congress is the only Parkinson’s conference that brings together all stakeholders in the Parkinson’s community — researchers, clinicians, people living with Parkinson’s, care partners, advocates, and industry professionals — in a single event. That inclusion is what makes WPC unique among Parkinson’s conferences.
The 2026 Phoenix congress covers the full spectrum of Parkinson’s disease — from motor symptoms and pharmacotherapy to non-motor features, neuroprotection, gene therapy, and quality of life research. Abstract submission is open and accepted presentations cover both scientific and lived experience perspectives.
Who should attend: Parkinson’s disease researchers, movement disorder specialists, neurologists, people living with Parkinson’s and their care partners, advocates, physical therapists, and allied health professionals in Parkinson’s care
CME / CPD Credits: CME credits available — verify on wpc2026.org
Website: https://wpc2026.org/
5. MDS International Congress 2026 — Parkinson’s Disease and Movement Disorders (Seoul)
Date: October 4–8, 2026
Location: COEX Convention and Exhibition Center, Seoul, South Korea
Theme: Understanding Aging in Movement Disorders
The MDS International Congress 2026 is the annual congress of the International Parkinson and Movement Disorder Society and the most scientifically rigorous Parkinson’s and movement disorders research event in the world. The 2026 Seoul meeting features 60+ timely scientific topics, hands-on skills workshops, live patient sessions, and real-world case analysis.
The congress offers up to 26.5 AMA PRA Category 1 CME credits — one of the highest concentrations of any movement disorders event. Live session translations in 60+ languages via AI captions make it the most globally accessible Parkinson’s congress in 2026.
Who should attend: Movement disorder specialists, Parkinson’s disease neurologists, neuroscience researchers in Parkinson’s, clinical trialists, and allied health professionals in movement disorder care
CME Credits: Up to 26.5 AMA PRA Category 1 CME Credits
Website: https://www.mdscongress.org/
6. Neuroscience 2026 — Society for Neuroscience (Washington, DC)
Date: November 14–18, 2026
Location: Walter E. Washington Convention Center, Washington, DC, USA
The SfN Annual Meeting is the largest neuroscience conference in the world and an essential event for basic neuroscientists working on the molecular and cellular underpinnings of Alzheimer’s and Parkinson’s. While it covers all of neuroscience rather than neurodegenerative diseases specifically, the sheer scale of the event — tens of thousands of attendees, thousands of abstract presentations — means the Alzheimer’s and Parkinson’s content alone would fill a conference.
Abstract submission opens May 27, 2026 and closes June 10, 2026. For basic neuroscientists working on tau, alpha-synuclein, amyloid, or neuroinflammation, SfN is the broadest platform available for presenting this work.
Who should attend: Basic and translational neuroscientists, neurodegeneration researchers, molecular biologists, pharmacologists, and PhD students with research relevant to Alzheimer’s or Parkinson’s biology
CME / CPD Credits: CME credits available — verify on sfn.org
Website: https://www.sfn.org/meetings/neuroscience-2026
7. CTAD 2026 — Clinical Trials on Alzheimer’s Disease Conference
Date: November 2026 — confirm dates on ctad-alzheimer.com
Location: USA — confirm venue on ctad-alzheimer.com
The Clinical Trials on Alzheimer’s Disease Conference is the most focused event in the world for clinical trialists and drug development researchers working specifically on Alzheimer’s disease. It covers phase 2 and 3 trial results, regulatory strategy, biomarker-driven trial design, and the translation of scientific discoveries into clinical interventions.
For pharmaceutical researchers, clinical neurologists involved in trials, and academics with Alzheimer’s drug development research, CTAD is the year’s most important publication-adjacent event — where trial readouts that will shape prescribing behaviour are first presented.
Who should attend: Clinical trialists, pharmaceutical researchers in Alzheimer’s drug development, neurologists involved in trial design, biomarker researchers, and regulatory affairs professionals in CNS
CME / CPD Credits: CME credits available — verify on ctad-alzheimer.com
Website: https://www.ctad-alzheimer.com/
8. SOBP Annual Meeting 2026 — Society of Biological Psychiatry
Date: May 2026 — confirm dates on sobp.org
Location: USA — confirm venue on sobp.org
The SOBP Annual Meeting is a critical event for researchers working on the biological mechanisms of neuropsychiatric conditions — including the neuropsychiatric aspects of Alzheimer’s and Parkinson’s diseases. Depression in Parkinson’s, psychosis in Alzheimer’s, and the intersection of neurodegeneration and psychiatric comorbidity are all active areas of presentation at SOBP.
For translational researchers who bridge laboratory neuroscience and clinical psychiatric manifestations of neurodegeneration, SOBP fills a gap that disease-specific conferences leave open.
Who should attend: Biological psychiatry researchers, translational neuroscientists, neuropsychiatrists, and clinicians managing psychiatric aspects of Alzheimer’s and Parkinson’s disease
CME Credits: CME credits available — verify on sobp.org
Website: https://sobp.org/2026-sobp-annual-meeting/
9. EAN Congress 2026 — European Academy of Neurology
Date: 2026 — confirm dates on ean.org
Location: European venue — confirm on ean.org
The EAN Congress is the most important neurology conference in Europe, drawing 5,000+ neurologists from 100+ countries. Alzheimer’s and Parkinson’s disease research features prominently across the programme each year — with dedicated sessions on neurodegeneration, cognitive neurology, movement disorders, and clinical trial updates in both conditions.
For European neurologists and researchers who want to stay current in Alzheimer’s and Parkinson’s without travelling to the USA or Asia-Pacific, EAN is the most comprehensive regional option.
Who should attend: European neurologists of all subspecialties, neurodegenerative disease researchers, movement disorder specialists, cognitive neurologists, and clinicians working in European Alzheimer’s and Parkinson’s care
CME Credits: European CME credits (ECMEC) available — verify on ean.org
Website: https://www.ean.org/congress2026
10. AD/PD™ 2027 — Barcelona, Spain (Plan Ahead)
Date: March 16–20, 2027
Location: Barcelona, Spain (Hybrid)
Abstract submission: Opens late 2026 — confirm at adpd.kenes.com
For researchers who missed the ADPD 2026 abstract deadline (which closed September 17, 2025), planning for 2027 starts now. The 21st AD/PD™ conference returns to Barcelona — one of Europe’s most accessible scientific hubs — for five days of neurodegenerative disease research across all areas of Alzheimer’s, Parkinson’s, and related disorders.
Barcelona 2027 will follow the same hybrid format as Copenhagen 2026, with both in-person and virtual attendance options. Watch adpd.kenes.com for the abstract submission opening date, which typically falls 5–6 months before the conference.
Who should attend: All researchers and clinicians working in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases who want the main annual meeting in the field
Website: https://adpd.kenes.com/
Quick comparison: Alzheimer’s and Parkinson’s conferences 2026
Use this table to find the best match for your goals and timeline.
| Conference | Hybrid | Abstract | CME | USA | 2026 |
|---|---|---|---|---|---|
| PubScholars Neurology 2026 ★ | Hybrid | ✓ | ✓ | ✓ | Nov 20–21 |
| AD/PD™ 2026 (Copenhagen) | Hybrid | Closed | ✓ | ✗ | Mar 17–21 |
| AAIC 2026 (London) | Hybrid | Limited | ✓ | ✗ | Jul 12–15 |
| WPC 2026 (Phoenix, USA) | In-person | ✓ | ✓ | ✓ | May 24–27 |
| MDS Congress 2026 (Seoul) | In-person | ✓ | ✓ | ✗ | Oct 4–8 |
| SfN 2026 (Washington DC) | Partial | ✓ | ✓ | ✓ | Nov 14–18 |
| AD/PD™ 2027 (Barcelona) | Hybrid | Open | ✓ | ✗ | Mar 16–20 |
All dates verified as of May 2026. ADPD 2026 and WPC 2026 have already taken place. Confirm all remaining events on official websites before registering.
How to choose the right conference for your research
If your research spans both Alzheimer’s and Parkinson’s
ADPD is the only conference that specifically integrates both conditions in a single scientific programme. For 2026, the Copenhagen meeting has already taken place. The next opportunity is AD/PD™ 2027 in Barcelona (Mar 16–20). If you need a 2026 option, the Neurology Conference 2026 (Nov 20–21, Boston) covers both Alzheimer’s and Parkinson’s research in its neurodegeneration sessions and has abstract submission open now.
If your research is specifically in Alzheimer’s disease
The AAIC 2026 (Jul 12–15, London) is the world’s largest Alzheimer’s-specific conference and the most likely venue for major dementia research announcements in 2026. CTAD 2026 (November, USA) is the top choice for clinical trial-focused Alzheimer’s researchers.
If your research is specifically in Parkinson’s disease
The 7th World Parkinson Congress (May 24–27, Phoenix) is unique in including patients and care partners alongside researchers. The MDS International Congress (Oct 4–8, Seoul) offers the most rigorous scientific programme and up to 26.5 CME credits.
If you want to present and get published in 2026
The Neurology Conferences 2026 (Nov 20–21, Boston) is the most accessible remaining option in 2026. Abstract submission is open, the review process is handled by an international scientific committee, and accepted papers are published in official conference proceedings. Submit at pubscholars.org/submit-abstract/.
If you are a basic neuroscientist working on disease mechanisms
The SfN Annual Meeting 2026 (Nov 14–18, Washington DC) is the broadest platform for presenting molecular and cellular neuroscience research. Abstract submission opens May 27, 2026.
Useful guides for researchers and conference attendees
These PubScholars resources will help you prepare:
- How to write a conference abstract — structure, format, and template specifically for neuroscience research
- What is the purpose of a conference committee — understand how your abstract is reviewed before submitting
- Top neuroscience conferences in 2026 — broader list covering SfN, AAN, FENS, and all major neurology events
- Conference papers vs journal papers — decide the right publication route for your Alzheimer’s or Parkinson’s research
- Guide to USA conference visa requirements — for international researchers attending WPC in Phoenix or SfN in Washington DC
Frequently asked questions — Alzheimer’s and Parkinson’s conferences 2026
What is the ADPD conference?
ADPD stands for Alzheimer’s Disease and Parkinson’s Disease. The AD/PD™ International Conference is the main annual gathering in the field of neurodegenerative diseases, bringing together thousands of scientists, clinicians, and industry professionals from over 60 countries to present the latest advances in research, diagnosis, and therapy for Alzheimer’s, Parkinson’s, and related disorders. What makes it distinctive is its integrative approach — studying both conditions in a single forum to explore their shared mechanisms and differences. It has been running since the early 1990s and became an annual event from 2022 onwards.
When and where was ADPD 2026?
AD/PD™ 2026 — the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders — took place March 17–21, 2026 at the Bella Center in Copenhagen, Denmark. It ran as a hybrid event with both in-person and online participation. The abstract submission deadline was September 17, 2025.
What is the next ADPD conference after 2026?
AD/PD™ 2027 takes place March 16–20, 2027 in Barcelona, Spain. It will follow the same hybrid format as the 2026 Copenhagen edition. Abstract submission is expected to open in late 2026. Visit adpd.kenes.com for current details and announcement dates.
Is there an Alzheimer’s and Parkinson’s conference in the USA in 2026?
Yes — two major ones. The 7th World Parkinson Congress (WPC 2026) ran May 24–27, 2026 at the Phoenix Convention Center in Arizona — covering all aspects of Parkinson’s disease with an inclusive community format. For researchers who want a 2026 USA event with abstract submission still open, the PubScholars Neurology Conference 2026 (Nov 20–21, Boston) covers Alzheimer’s and Parkinson’s research in a hybrid format. Submit at pubscholars.org/submit-abstract/.
What is the difference between ADPD and AAIC?
ADPD (AD/PD™) covers both Alzheimer’s disease AND Parkinson’s disease together — exploring their shared mechanisms and overlapping biology. AAIC (Alzheimer’s Association International Conference) covers Alzheimer’s disease and dementia only. ADPD is the broader neurodegenerative disease event; AAIC is the deeper Alzheimer’s-specific one. Many researchers working on Alzheimer’s attend both.
Where can I present Parkinson’s or Alzheimer’s research in 2026 with abstract submission still open?
The PubScholars Neurology Conference 2026 (November 20–21, Boston, MA) has abstract submissions open now at pubscholars.org/submit-abstract/. The SfN Annual Meeting (Nov 14–18, Washington DC) opens abstract submission May 27, 2026. The MDS Congress (Oct 4–8, Seoul) and CTAD 2026 (November, USA) also have submission opportunities — check official websites for current deadlines.
Plan your neurodegenerative disease conference calendar
The conferences on this list represent the full spectrum of Alzheimer’s and Parkinson’s research in 2026 — from the integrative neurodegenerative science of ADPD and the Alzheimer’s-specific depth of AAIC, to the Parkinson’s community breadth of WPC and the clinical rigour of MDS.
For researchers who want an accessible hybrid event with abstract submission open and publication in conference proceedings, the PubScholars International Neurology Conference 2026 (November 20–21, Aloft Boston Seaport District, Boston, MA) is the strongest remaining option in 2026.
I am a seasoned professional with over 9 years of transformative experience in the domains of molecular biology, immunology, and clinical research. With a career that spans from 2006 to 2018, my journey has been marked by a relentless pursuit of scientific excellence and an unwavering commitment to improving healthcare outcomes through groundbreaking research. I have worked at one of India’s premier medical institutions, AIIMS(All India Institute of Medical Sciences), where I contributed significantly to the fields of molecular biology and clinical research. My expertise in protein analysis and genetic studies allowed me to identify potential biomarkers and improve diagnostic accuracy, contributing to better healthcare outcomes for patients. Notably, the research work has been published in prestigious scientific journals such as the Indian Journal of Ophthalmology and the British Journal of Ophthalmology.
Publication in these esteemed journals reflects my commitment to advancing medical science and sharing insights with the global research community. These publications highlight my expertise in areas ranging from gene polymorphism and immune response mechanisms to the effects of chronic drug therapy, all contributing to the larger body of scientific knowledge. My passion for scientific communication led me to pursue an Executive Diploma in Medical Writing from CliMed Research Solutions and Curio Training and Research Institute (CTRI), India. This certification has further refined my ability to bridge the gap between complex scientific research and its practical applications in healthcare. My passion for content writing drives me to continuously create content that derives engagement ,build trust, and leaves a lasting impression on readers”.
